Allergan Settles InnoPharma Patent Suit Over Restasis

Oct 12, 2017

Dublin-based Allergan announced that it has reached an agreement with InnoPharma Inc. to settle patent litigation regarding its patents covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%. The patents are listed in the Orange Book and expire on August 27, 2024.

Allergan will grant InnoPharma licenses to market a generic version of Restasis in the United States beginning on Feb. 24, 2024, or earlier in certain cases. Also, under special circumstances, Allergan will authorize InnoPharma to launch an authorized generic version of Restasis on Aug. 28, 2024.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments